Sirona Dental Systems (Nasdaq: SIRO) reported earnings on Nov. 16. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q4), Sirona Dental Systems beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.

Margins grew across the board.

Revenue details
Sirona Dental Systems logged revenue of $247.4 million. The 13 analysts polled by S&P Capital IQ hoped for sales of $225.8 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $218.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.71. The 14 earnings estimates compiled by S&P Capital IQ forecast $0.70 per share. GAAP EPS of $0.62 for Q4 were 158% higher than the prior-year quarter's $0.24 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 53.4%, 280 basis points better than the prior-year quarter. Operating margin was 18.4%, 850 basis points better than the prior-year quarter. Net margin was 14.0%, 770 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $270.6 million. On the bottom line, the average EPS estimate is $0.93.

Next year's average estimate for revenue is $1.03 billion. The average EPS estimate is $3.37.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 106 members out of 118 rating the stock outperform, and 12 members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Sirona Dental Systems a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sirona Dental Systems is buy, with an average price target of $60.39.